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Accepted 18 January 2016In this study, protein microarrays based on sandwich immunoassays are generated to quantify the amount of
alpha fetoprotein (AFP) in blood serum. For chip generation a mixture of capture antibody and a photoactive co-
polymer consisting of N,N-dimethylacrylamide (DMAA), methacryloyloxy benzophenone (MaBP), and Na-4-
styrenesulfonate (SSNa) was spotted onto unmodiﬁed polymethyl methacrylate (PMMA) substrates. Subse-
quently to printing of the microarray, the polymer and protein were photochemically cross-linked and the
forming, biofunctionalized hydrogels simultaneously bound to the chip surface by short UV- irradiation. The
obtained biochip was incubated with AFP antigen, followed by biotinylated AFP antibody and streptavidin-Cy5
and theﬂuorescence signal read-out. The developedmicroarray biochip covers the range of AFP in serum samples
such asmaternal serum in the range of 5 and100 ng/ml. The chip production process is based on a fast and simple
immobilization process, which can be applied to conventional plastic surfaces. Therefore, this proteinmicroarray
production process is a promising method to fabricate biochips for AFP screening processes.








Alpha fetoprotein (AFP), a glycoprotein with a molecular weight of
approximately 70 kDa, is the most abundant plasma protein found in
human fetus. However, the plasma level decreases rapidly to normal
adult levels during the ﬁrst year of life. Normally, AFP is present only
at rather low levels in the blood of healthy people (reference value
b10 ng/ml) [1]. Certain types of cancers and liver diseases are known
to lead to increased AFP levels. Accordingly, AFP is widely used as a
serum biomarker for hepatocellular carcinoma (HCC) screening in pa-
tients [2] and for HCC diagnosis [3]. Unusual AFP levels during pregnan-
cy in thematernal blood or in the amniotic ﬂuid are taken as serological
soft markers for congenital malformation (e.g. open neural tube defects,
anencephaly) or chromosome anomalies. An unusually low value
(depending on the stage of gestation) might serve as an indication of), boonsong@sut.ac.th
emsak.sri@mahidol.ac.th
(T. Brandstetter),
abhiban5 Street, Soi32, Sai Mai
. This is an open access article underthe presence of the Down-Syndrome (Trisomie-21) in the developing
fetus [4–7].
As of today several techniques have been developed for AFP detec-
tion, for example electrochemical immunosensors [8,9], colorimetric
detection [10–12] and piezoelectric biosensors [13]. Most of these tech-
niques utilize covalent binding reactions to immobilize the antibody
onto the sensing surface [8–11]. Immobilization via covalent binding re-
quires several steps including surface preparation and activation to pro-
vide appropriate reactive surface groups, and antibody immobilization.
In general, immobilization by practically all methods know today is a
multi-step processwhich is time and resource consuming and increases
the risk of quality problems in the production process.
The surface area available for binding of the probe molecules is an
important factor for immobilization. When self assembled monolayers
are employed, the surface density of capture molecules is intrinsically
limited. Additionally, at high surface concentrations the intermolecular
distances of the boundmolecules are decreased, whichmight inﬂuence
the accessibility for target molecules. A too dense binding can result in
steric hindrance andmight reduce the efﬁciency of immobilization pro-
cess [14,15]. To increase the surface density of accessible biomolecules
on a sensor surface, immobilization based on surface-attached very
thin hydrogel pads has been developed which allow a more three di-
mensional arrangement of the molecules [15,16].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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by a rapid photoreaction of a photopolymer with an unmodiﬁed
PMMA substrate. The photoactive polymer is a terpolymer based on
water soluble dimethylacrylamide (DMAA), the photo-crosslinker
methacryloyloxy benzophenone (MaBP) and Na-4-styrenesulfonate
(SSNa). A mixture of the photopolymer and the protein capture mole-
cules is printed onto the substrate, followed by brief UV-irradiation.
The described photo-immobilization process is applied to fabricate sen-
sor chips for AFP detection. The detection range, sensitivity and speciﬁc-
ity of this protein microarray biochip are determined.
2. Materials and methods
2.1. Materials
Commercial grade PMMA slides, which were used as substrates,
were cleaned with methanol for 5 min before printing. Capture anti-
body (mouse anti-human AFP) and detection antibody (biotinylated
chicken anti-human AFP) were obtained from R&D Systems (UK). AFP
antigen was obtained from MyBiosource (USA). Streptavidin-Cy5 was
purchased from Life Technologies (USA). Bovine serum albumin (BSA)
used as a blocking was obtained from Sigma Aldrich (A7030). Two
cytokines were used for the speciﬁcity tests, which are tumor necrosis
factor alpha (TNFα) and interleukin (IL-8) purchased from Gibco (Life
Technology). 10 mM phosphate buffered saline pH 7.4 (PBS; Sigma
Aldrich, St. Louis, MO) was used to dilute the capture antibody and
streptavidin-Cy5. A dilution buffer (DY995, R&D Systems, UK) was
used to dilute detection antibody and AFP antigen.
2.2. Microarray fabrication
The printing solution is prepared from amixture of the proteins cap-
ture molecules and a photoactive copolymer consisting of N,N-
dimethylacrylamide (DMAA, 92.5 mol% (w/w)), methacryloyloxy ben-
zophenone (MaBP, 5 mol% (w/w)), and Na-4-styrenesulfonate (SSNa,
2.5 mol% (w/w)) (Fig. 1). The copolymer was synthesized using a stan-
dard free radical polymerization process as described previously [17].
The copolymerwas dissolved in deionized (DI)water at a concentration
of 10 mg/ml prior to mixing with protein solutions which were diluted
in PBS to yield the concentrations given in the individual experiments.Fig. 1. Schematic depiction of the chemical structure of the copolymer used for the micro
benzophenone groups are used to simultaneously crosslink the polymer, bind the biomoleculeThe ﬁnal polymer content in printing solution was 1 mg/ml. Printing
of the protein arrays was performed under clean room conditions at a
temperature of 22 °C and a relative humidity of 40%. The volume per
spot was 1.6 nl. Untreated commercial PMMA slides were used as sub-
strates. Protein immobilization is achieved through irradiation with
UV-light at a wavelength of 254 nm with energy of 0.5 J/cm2. A sche-
matic of the layout of the AFP protein microarray is shown in Fig. 2.2.3. Assay procedure
For isolating reaction sites on larger substrates carryingmultiple mi-
croarrays, 25 μl Frame Seals (Thermo scientiﬁc) were used to create in-
dividual wells. The surfaces of the protein microarrays were blocked
with 0.1% (w/v) BSA in PBS for 1 h to reduce non-speciﬁc binding.
After that, the microarrays were incubated with various concentrations
of AFP antigen for 2 h, 2 μg/ml of detection antibody for 2 h, and
streptavidin-Cy5 in a ratio of 1:200 for 15 min, respectively. Before
every step of incubation, protein microarrays were washed with PBS
to remove unbound molecules from the biochip. The ﬂuorescence in-
tensity was read out after completing the assay.
In order to avoid probes with non-speciﬁc binding of blood compo-
nents to the surfaces, all test liquids were diluted 1:100 using the dilu-
tion buffer given above. The thus obtained AFP standard solutions had
the following concentrations: 0.000, 0.005, 0.010, 0.025, 0.050, 0.100,
0.250, 0.500, 1.000, 2.500, 5.000, and 10.000 ng/ml. The speciﬁcity
of the protein microarrays was tested against BSA, TNFα, and IL-8
which were diluted in reagent diluents. Fluorescence intensities were
quantiﬁed by the software SignalyseTM(Holger Klapproth Life Science,
Germany).2.4. Instrumentation
Protein microarrays were produced with a contactless dispenser
(SciFlexArrayer S3, Scienion AG, Germany) and after completion of
the print irradiated with UV-light (Stratagene Europe, Amsterdam,
The Netherlands). Read-out of microarrays was performed using
a SensoSpot©-Sensovation's ﬂuorescence array imaging reader
(Germany).array fabrication (upper) and the platform of AFP detection (lower). The photoactive
, and attach the forming hydrogel to the surface.
Fig. 2. Schematic depiction of the biochip layout. The 1st columnwas printedwith streptavidin-Cy5 at a ratio of 1:200 as a coupling control (CC). The 2nd, 3rd, 4th, and 5th columns were
spottedwith 10, 50, 100, and 200 μg/ml of capture antibody (Cap.), respectively. The 6thwas generated as detection control (DC)which is detection antibody. The 7th columnwas printed
as negative control (NC) which is a printing solution without protein. Each column consists of 6 identical spots.
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3.1. Protein microarray fabrication
The protein solutions in PBS bufferweremixedwith the photoactive
copolymer and printed onto PMMA substrate using a piezo printer. The
copolymer consists of poly(dimethylacrylamide) (PDMAA) as a hydro-
philic matrix component. Sodium styrenesulfonate (SSNa) repeat
units are incorporated to introduce charges to the polymer and enhance
solubility of the ﬁnal copolymer inwater andMaBP to provide photo re-
active benzophenone groups to the polymer [17]. After printing of the
polymer/protein mixtures, the dispensed drops dry rather rapidly. Dur-
ing irradiation with UV-light the benzophenone units become activated
into a biradicaloid triplet state and the reactive intermediate undergo
C,H insertion reactions. In the course of this process three reactions
occur simultaneously [18]: 1) transformation of the water soluble poly-
mer into a hydrogel, 2) covalent linking of the forming hydrogel to the
substrate and 3) immobilization of the protein added to the printing so-
lution to the hydrogel via covalent binding [15,17].
The amount of capture antibody bound to the sensor surface can be
controlled by varying the concentration of proteins in the printing solu-
tion and the volume of the deposited drops. Moschallski et al. [15] have
shown that a higher binding capacity was obtained in the hydrogels
when compared with the monolayer [15].
3.2. AFP detection
A schematic depiction of the AFP detection is shown in Fig. 1. After
immobilization of the capture antibody as described above and incuba-
tion with the analyte solution, the latter was detected by conjugation
with a biotinylated anti-AFP antibody and streptavidin-Cy5 conjugation.
Fluorescence images of chips after incubation with solutions of various
AFP concentrations are shown in Fig. 3. The coupling control (CC; 1st
column) and detection control (DC: 6th column) were used to check
the immobilization process. The negative control does not yield any
ﬂuorescence signal (NC; 7th column) and is used to obtain the back-
ground signal.
The results in Fig. 3 showed that at a concentration of 0.010 ng/ml of
AFP a clear signal could be observed for spots printed at a concentration
of 200 μg/ml capture antibody (5th column). When the capture anti-
body concentration was lower (100 and 50 μg/ml) (4th and 3rd col-
umn) the lowest concentration at which signals could be observed
were 0.025 and 0.050 ng/ml of AFP, respectively. For even lower con-
centration of the spotting solution, (10 μg/ml capture antibody (2nd col-
umn)), the obtained ﬂuorescence spot images were still visible, but
could no longer be used for protein quantiﬁcation.3.3. Calibration curve
The highest signal intensity of the ﬂuorescence images could
be obtained on spots generated from 200 μg/ml capture antibody so-
lutions and decreased for lower antibody concentrations (100, 50
and 10 μg/ml). This indicated that antibodies are immobilized in
the ﬂexible, highly swollen hydrogel, which allows easy access of
the antigens to the immobilized antibody. The ﬂuorescence signals
obtained from 10 μg/ml capture antibody were only rather weak and
accordingly had a high noise level. For all other spot locations the
ﬂuorescence signal seemed to be saturated at about 1 to 2 ng/ml of
AFP. The highest detection slope of the ﬂuorescence signal as a
function of the AFP concentration and thus highest sensitivity
was obtained on spots generated from 200 μg/ml capture antibody
(Fig. 4). This indicates that the surface concentration of the capture pro-
teins in the hydrogel spots is still not so high that the binding capacity is
becoming compromised.
3.4. Limit of detection
To determine the limit of detection of the protein microarray bio-
chip, signal-to-background ratio (SBR) was determined as a function
of the antibody concentration during chip printing. When a comparison
of the results of the chip analysis with the concentration range relevant
for diagnostic is made, it should be noted that for all following experi-
ments the solutions were diluted by a factor of 1:100. The SBR in
these experimental series was deﬁned as the quotient of ﬂuorescence
intensities of probe containing hydrogel and empty spots. Fig. 5 shows
the SBR of 3 different biochips measured at concentrations of 0.005,
0.010, 0.025, and 0.050 ng/ml of AFP antigen. The results indicated
that the limit of detection of the biochip (at least for the higher antibody
concentrations) was 0.010 ng/ml and the limit of quantiﬁcation
0.050 ng/ml for which an SBR above 10 is required. For maximal re-
sponse a concentration of the capture antibody of 200 μg/ml should be
chosen.
3.5. Speciﬁcity of the protein microarray biochip
To evaluate the speciﬁcity of this biochip, AFP determination was
carried out in the presence of 2 cytokines (TNFα and IL-8) and a typical
blood protein (BSA). These proteins were added as model compounds
(0.1 ng/ml) to check for possible interference with other proteins pres-
ent in the analyte. As shown in Fig. 6 the addition of TNFα, IL-8 and BSA
resulted only in a very small increase of the background ﬂuorescence
signal. This is not surprising as it has been shown, that such surface-
Fig. 3. Fluorescence images biochips after exposure to various AFP concentrations: 0.0, 0.005, 0.010, 0.025, 0.050, 0.100, 0.250, 0.500, 1.000, 2.500, 5.000, and 10.000 ng/ml.
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the unspeciﬁc adsorption of proteins [19]. Accordingly, the ratio be-
tween speciﬁc and non-speciﬁc signal still remained almost at a factor
of 55 for the mixed molecules so that any potential interference of the
added proteins during AFP quantiﬁcation can be neglected.Fig. 4. Relationships between ﬂuorescence intensity and AFP concentrations on different
surface density of capture antibody: 10 μg/ml (black square), 50 μg/ml (red circle),
100 μg/ml (blue up-pointing triangle) and 200 μg/ml (green down-pointing triangle).4. Conclusion
In this study, a rapid photo-immobilization process based on C,H in-
sertion reactions was successfully applied to fabricate protein microar-
rays for the detection and quantiﬁcation of alpha fetoprotein (AFP).Fig. 5. Signal-to-background ratios (SBR) indicating the limit of detection value (above
SBR = 3) of chips printed with solution containing 10, 50, 100, and 200 μg/ml capture
antibody.
Fig. 6. Speciﬁcity of protein microarray biochip toward AFP antigen (0.1 ng/ml) against
other biomolecules (0.1 ng/ml): TNFα (tumor necrosis factor alpha), IL-8 (interleukin)
and BSA (bovine serum albumin).
99S. Yodmongkol et al. / Sensing and Bio-Sensing Research 7 (2016) 95–99Microarray printing of a mixture of probemolecules and photopolymer
followed by brief UV-exposure is sufﬁcient to generate proteinmicroar-
rays, which allow quantiﬁcation of AFP over the whole concentration
range required in diagnostics, i.e. between 5 and 100 ng/ml. The sensi-
tivity of the developed chip is so high that all analyte solutions need
to be diluted by 100 times in order to avoid overloading of the surface,
whichwould prevent quantiﬁcation. After dilution a linear response be-
tween concentration and read-out signal was observed.
An additional interesting aspect of the developedmethod is that un-
modiﬁed plastic chips can be used as substrates so that the array gener-
ation is fast and inexpensive. Currently studies are under way which
aim at the integration of further markers on the chip and on the valida-
tion of the produced chips in diagnostic tests performed in a clinical
setting.
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